User login
Key clinical point: Patients with inflammatory bowel disease (IBD) who switched from one infliximab biosimilar to another had no adverse impact on infliximab trough levels and clinical disease activity, regardless of whether switching for the first or second time.
Major finding: Median infliximab trough levels were higher after vs before switch (5.5 vs 4.9 μg/mL; P = .007). C-reactive protein (P = .43) and disease activity scores (P = .82) did not change significantly before vs early after switch, regardless of whether switching for the first or second time; the proportion of patients in remission also did not change significantly (91% vs 92%; P = .75).
Study details: Findings are from a prospective observational cohort study of 222 patients with IBD treated with infliximab biosimilar CT-P13 who underwent a nonmedical switch to SB2, of which 99 patients underwent a second switch.
Disclosures: No funding interests were declared. RP Luber, S Honap, MA Samaan, and PM Irving declared receiving grants and serving as speaker, consultant, and/or on advisory board for various sources.
Source: Luber RP et al. Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
Key clinical point: Patients with inflammatory bowel disease (IBD) who switched from one infliximab biosimilar to another had no adverse impact on infliximab trough levels and clinical disease activity, regardless of whether switching for the first or second time.
Major finding: Median infliximab trough levels were higher after vs before switch (5.5 vs 4.9 μg/mL; P = .007). C-reactive protein (P = .43) and disease activity scores (P = .82) did not change significantly before vs early after switch, regardless of whether switching for the first or second time; the proportion of patients in remission also did not change significantly (91% vs 92%; P = .75).
Study details: Findings are from a prospective observational cohort study of 222 patients with IBD treated with infliximab biosimilar CT-P13 who underwent a nonmedical switch to SB2, of which 99 patients underwent a second switch.
Disclosures: No funding interests were declared. RP Luber, S Honap, MA Samaan, and PM Irving declared receiving grants and serving as speaker, consultant, and/or on advisory board for various sources.
Source: Luber RP et al. Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
Key clinical point: Patients with inflammatory bowel disease (IBD) who switched from one infliximab biosimilar to another had no adverse impact on infliximab trough levels and clinical disease activity, regardless of whether switching for the first or second time.
Major finding: Median infliximab trough levels were higher after vs before switch (5.5 vs 4.9 μg/mL; P = .007). C-reactive protein (P = .43) and disease activity scores (P = .82) did not change significantly before vs early after switch, regardless of whether switching for the first or second time; the proportion of patients in remission also did not change significantly (91% vs 92%; P = .75).
Study details: Findings are from a prospective observational cohort study of 222 patients with IBD treated with infliximab biosimilar CT-P13 who underwent a nonmedical switch to SB2, of which 99 patients underwent a second switch.
Disclosures: No funding interests were declared. RP Luber, S Honap, MA Samaan, and PM Irving declared receiving grants and serving as speaker, consultant, and/or on advisory board for various sources.
Source: Luber RP et al. Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.